semaj83/ctmatch_classification huggingface dataset:
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Systemic Lupus Erythematosus Fulfill ACR Classification for SLE >18 and < 60 years old English-speaking/reading Has a treating rheumatologist at the Hospital for Special Surgery Estimated premorbid verbal I.Q. >80 measured by the North American Adult Reading Test Functional difficulties due to cognitive dysfunction defined as positive endorsement of ≥6 items on the Cognitive Symptoms Inventory (CSI). The CSI is a 21-item, self-report questionnaire designed to assess ability to perform everyday activities in patients with rheumatic disease.47 No physical or mental disabilities that would preclude or confound the results of the neuropsychological testing, e.g., compromised use of hands, severe visual or hearing impairment Able to read normal newsprint and hear a normal speaking voice Normotensive at time of enrollment with or without medication No arrhythmia or left ventricular hypertrophy on ECG  Global cognitive impairment as measured by a Modified Mini Mental Status<77 History of arrhythmia; known history of left ventricular hypertrophy, mitral valve prolapse with syndrome, or other significant cardiovascular disease with a reduced ejection fraction Renal insufficiency (creatinine clearance < 30 ml/min) including dialysis patients Known liver disease (e.g., active hepatitis) or any liver function test >2x upper limit of normal (transaminases or GGTP) Significant and serious SLE activity defined as active central nervous system disease, active nephritis, ulcerative skin disease. Other active SLE-associated conditions involving major organ systems may be excluded at the discretion of the investigator Pregnancy, nursing mother, or unwillingness to use barrier contraception Diagnosis of active psychosis, ADHD, ADD Current use of medications contraindicated with the use of modafinil-triazolam, Phenobarbital, cyclosporine A, theophylline, carbamazepine, diazepam, phenytoin, mephenytoin, rifampin, ketoconazole, itraconazole Illegal drug or alcohol abuse (defined as two affirmative responses to the CAGE questionnaire) Prior use of modafinil
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Lupus Nephritis Have renal biopsy proven Lupus Nephritis (with the biopsy-based diagnosis date no earlier than January 1, 1995) Reside within designated counties of eastern North Carolina and South Carolina
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rash Non-small-Cell Lung Cancer To be eligible for the study, subjects must fulfill all of the following Be male or female ≥18 years of age (inclusive) Have been prescribed Tarceva as a single agent to treat locally advanced or metastatic NSCLC, after failing at least 1 prior chemotherapy regimen Present with acute signs and symptoms of rash on the face that meet the following Are suspected to be related to Tarceva at least 3 inflammatory lesions, and Are less than CTCAE Grade 3 in severity Have an Eastern Co-operative Oncology Group (ECOG) performance status ≤2 and a life expectancy of at least 4 months Sign an approved informed consent form for the study Be willing to comply with the protocol  Subjects meeting any of the following will be excluded from the study A skin examination reveals the presence of another skin disease and/or condition (excessive facial hair, excessive scarring, sunburn, or other disfigurement) located on the face that, in the study physician's opinion, would confound the evaluation of the rash A diagnosis of G6PD deficiency, defined as having a G6PD value below the lower limit of normal A diagnosis of anemia, defined as hemoglobin <9.5 g/dL Undergoing any current therapy for NSCLC other than Tarceva Prior treatment with Iressa, Erbitux, or any experimental HER1/EGFR inhibitor Treatment with topical antibiotics, topical steroids, and other topical treatments on the face within 14 days of Day 0 (start of study treatment) Treatment with any systemic antibiotics within 7 days of Day 0 (start of study treatment) Treatment with any systemic medication or therapy known to affect anti-inflammatory responses within 30 days prior to Day 0 (start of study treatment). These medications but are not limited to, oral corticosteroids, cyclosporine, and methotrexate. Short-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs) before the study for non-rash related conditions is acceptable, provided that exposure is limited to ≤7 days per course. Chronic low-dose aspirin use is also acceptable Active participation in an experimental therapy study or received experimental therapy within 30 days of Day 0 (start of study treatment)
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  SLE Rheumatoid Arthritis Healthy Subjects SLE, RA, healthy
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atherosclerosis Thromboembolism Systemic Lupus Erythematosus Age > 18 years Fulfillment of at least 4 of the American College of Rheumatology (ACR) for SLE Presence of any two of the following risk factors SLE duration of >= 5 years Postmenopausal Age >= 40 years Diabetes mellitus Hypertension (140/90 mmHg) Serum low density lipoprotein (LDL) level >= 2.6 mmol/L or total cholesterol >= 5.5 mmol/L Obesity (body mass index >= 27 kg/m2)  Patients with known allergy to aspirin, or any other non-steroidal anti-inflammatory drugs (NSAIDs), or statins Patient with a history of severe gastrointestinal intolerance to aspirin (e.g., gastrointestinal bleeding) or other NSAIDs Patients with history of arterial or venous thromboembolism Patients receiving aspirin or other anti-platelet agents Patients receiving long-term non-aspirin NSAIDs Patients receiving anticoagulation therapy (e.g., warfarin) Patients with history of intolerance or allergy to the statins Pregnant or lactating women
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Systemic Lupus Erythematosus Eligible women will be those having any two of the following Amenorrhea of 6 months or more Serum follicle-stimulating hormone level of 30 IU/L or more Menopausal symptoms Age 48 years or older  Women older than 65 years Severe lupus activity at baseline (SLEDAI score, more than 30) Use of estrogens within 3 months of the screening visit Serum creatinine of 2.0 mg/dL or more Hypertriglyceridemia 500 mg/dL or more Metabolic bone diseases Liver disease Untreated hyperthyroidism Recent thrombosis Malignancy
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Age of 18 and above Diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology (ACR) Classification Criteria Treatment with HCQ for at least 6 months, without modification of HCQ dosage for 2 months Stable dosage of HCQ from one day to another (200 g x 2/day or 400 mg once a day or 200 mg once a day) No increase in the steroids dosage during the 3 previous weeks Steroids dosage lower or equal to 0. 5 mg/kg/day of prednisone equivalent No modifications of a possible immunosuppressor during the 2 previous months < or = 12 Signature of the consent of participation  Known retinopathy, present or passed Severe cataract obstructing the ophthalmologic monitoring patients Past history of intolerance with HCQ (in particular gastro-intestinal, or retinal) during the possible former use of a higher dosage Use of nivaquine during the 3 previous months Treatment with biotherapy (for example Rituximab) during the 12 previous months Calculated clearance of creatinin lower than 60 ml/min Chronic alcoholism Liver failure Desire of pregnancy in the next 7 months
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE) as defined by meeting at least 4 of the 11 classification of the American College of Rheumatology for the classification of Systemic Lupus Erythematosus, either sequentially or coincident. The 4 need not be present at study entry Renal biopsy within 12 months prior to screening visit indicating active proliferative lupus glomerulonephritis (met ISN/RPS Class III or IV classification [2003], excluding Class III [C], IV-S [C] and IV-G [C], or the World Health Organization Class III or IV classification [1982], excluding Class IIIc, IVd). If the renal biopsy was performed >3 months but ≤12 months prior to screening visit, at least 1 of the following 3 serologies (performed locally) must have been abnormal prior to screening visit: complement (C3 or C4) level below normal range OR anti-dsDNA >upper limit of normal range A stable serum creatinine ≤3 mg/dL  Subjects with a rise in serum creatinine of ≥1 mg/dL within 1 month prior to the screening visit Subjects with drug-induced SLE, as opposed to idiopathic SLE Subjects with severe, unstable and/or progressive Central nervous system (CNS) lupus Subjects with autoimmune disease other than SLE as their main diagnosis (e.g.; Rheumatoid arthritis (RA), Multiple Sclerosis [MS]) Subjects who have received treatment with cyclophosphamide within 3 months of randomization (Day 1) Subjects who have received treatment with rituximab < 6 months prior to the screening visit
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus men and women with diagnosis of SLE years and above negative pregnancy test for female subjects of child-bearing age and must accept not to attempt to get pregnant during the period of the study Subject with active disease as defined by SLAM of at least 8 SLICC/ACR damage index of less or equal to 15 Subject must be on stable does of NSAIDs, prednisone, or antimalarial (chloroquine sulfate or hydroxychloroquine) at least 4 weeks preceding the study subjects can be under other medications as long as condition or treatment will not interfere with the experimental medications and assessments must understand either French or English and can give written informed consent  previous history of hypersensitivity or intolerance to methotrexate or folic acid total SLAM of less than 8 or total SLICC/ACR score of more than 15 history of medical non-compliance or inability to comply with instructions subject who have received intra-articular or intramuscular corticosteroids in the four weeks prior to study entry clinically significant acute or chronic liver disease with the exception of autoimmune liver disease alcohol use in excess of 2 ounces of 100 proof liquor or its equivalent/week insulin requiring diabetes mellitus with morbid obesity renal impairment such that the serum creatinine is more than or equal to 175 umol/I (SI units) or 2.0 mg/dl interstitial lung disease as defined by an abnormal chest x-ray or decrease diffusion capacity (DLCO < 70% of predicted) without evidence of pulmonary hypertension WBC count ,3,000/ cubic mm. and/or platelet count ,80,000/ cubic mm
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Males or females, aged 18 years and over Patients meeting the diagnostic for SLE (Appendix 2), according to ACR guidelines (including screening for anti-dsDNA (antibody to native DNA in abnormal titer)) > 6 Patients treated with maintenance therapy including azathioprine Patients who are willing and able to participate in the study and from whom written informed consent has been obtained  Creatinine clearance of < 20ml/min Patients with any clinically significant infection Patients with known hypersensitivity to myfortic ® or to drugs with similar chemical structures Patients with a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin Patients with SLE active CNS manifestations or a past history of SLE CNS complications (e.g. psychosis, grand mal seizures) Patients who have received prior therapy with mycophenolic acids (MPAs) (e.g. MMF) Patients who have received an investigational drug within four weeks prior to study entry Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Cutaneous Lupus Diagnosis of Systemic Lupus Erythematosus or Cutaneous Lupus Patient of a rheumatologist at Duke University Medical Center  Inability to travel to Duke for follow-up visits Inability to speak English Not able to provide informed consent
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lupus Nephritis age at least 18 years diagnosis of SLE by ACR diagnosis of proliferative lupus nephritis (ISN/RPS class III or IV) currently on prednisolone (5 to 20 mg/day) in partial or complete remission for at least 3 months  currently pregnant in end-stage renal failure receiving corticosteroids for an indication other than lupus nephritis
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 0.0-21.0,  Lupus Age: Less than 21 years at baseline exam Diagnosis: patients must meet for one of five diagnostic categories based on classification according to three parameters; aPL positivity, APS and SLE criteria The five diagnostic categories are SLE with no aPL SLE with aPL, but without manifestations of APS SLE-like APS SLE with APS Primary APS
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 7.0-22.0,  Lupus Erythematosus, Systemic SlE subjects 4/11 of the American College of Rheumatology for SLE (23), age less than 22 years  Neonatal SLE or drug-induced SLE Subjects who are pregnant, and subjects weighing over 300 pounds, as the densitometry techniques are not reliable above this weight Subjects receiving calcium or vitamin D supplementation will not be excluded but this information will be recorded and evaluated further in the dietary/nutritional assessment
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Lupus Erythematosus, Systemic age 18 to 65 years SLE as defined by the ACR classification Stable SLE (treatment not modified during the 2 months preceding the date W0) SLE treated by immunosuppressant only or systemic corticosteroids at a dose ≥ 5 mg/j or systemic corticosteroids at any dose associated with one or more immunosuppressive drugs SLE treated by hydroxychloroquine only months following females must have an effective method of contraception during the first 7 months of the study and with a negative serum or urinary pregnancy test females not wishing to have a child during the 7 months following W0 physical examination signed written and informed consent  pregnant females or females wishing to have a child during the 7 months following W0 subjects infected with HIV and/or HBV( Ag HBs+) and or HVC medical history of allergy to any vaccine component receipt of any pneumococcal vaccine less than 5 years receipt of other vaccine within one month prior to enrolment (inclusion visit W0) receipt of immunoglobulin within three months prior to enrolment (inclusion visit W0) splenectomy hematopoietic disorders which give contra-indications to intramuscular and hypodermic route injections active malignancy , cirrhosis intercurrent illness within one month prior to enrolment (inclusion visit W0)
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Eythematosus (SLE) Fulfill the revised ACR for SLE with either evidence of active disease according to SLE Disease Activity Index (SLEDAI)  Patients who are pregnant or nursing women, or those with life threatening disease
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Written Informed consent Age >18 yrs SLE meeting ACR {Tan, Cohen, et al. 1982 1482 /id} for at least 6 months.(SLE group) Stable disease activity as evidenced by no change in immunosuppressive therapy in the past 1 month If female of childbearing potential must use an effective method of birth control  Renal disease (creatinine >1.5 mg/dL, dialysis, 2+ or more proteinuria) Previous or current history of peptic ulcer disease or gastrointestinal bleed Previous or current thromboembolic or ischemic cardiovascular event (stroke, myocardial infarction, angina) can do aspirin part of study Currently taking an anticoagulant or antiplatelet agent (besides aspirin) Thrombocytopenia (platelet count <135,000) Pregnancy Allergy to aspirin, NSAIDs NSAIDs in the previous week